Posted by Michael Wonder on 07 Oct 2022
Pembrolizumab in combination with platinum-based chemotherapy for treating recurrent, persistent or metastatic cervical cancer
5 October 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of pembrolizumab in combination with platinum-based chemotherapy in the NHS in England.
Pembrolizumab, when used in combination with chemotherapy with or without bevacizumab is not recommended for the treatment of adults with persistent, recurrent, or metastatic cervical cancer whose tumours express programmed cell death ligand 1 with a combined positive score of at least 1.
